Affordable Access

deepdyve-link
Publisher Website

Preliminary evaluation of YUTIQ™ (fluocinolone acetonide intravitreal implant 0.18 mg) in posterior uveitis

Authors
  • Testi, Ilaria1
  • Pavesio, Carlos1
  • 1 Moorfields Eye Hospital, NHS Foundation Trust, 162 City Rd, London EC1V 2PD, UK
Type
Published Article
Journal
Therapeutic Delivery
Publisher
"Future Science, LTD"
Publication Date
Oct 30, 2019
Volume
10
Issue
10
Pages
621–625
Identifiers
DOI: 10.4155/tde-2019-0051
PMID: 31663454
PMCID: PMC6880290
Source
PubMed Central
Keywords
Disciplines
  • Device Evaluation
License
Unknown

Abstract

Uveitis is a major cause of ocular morbidity, potentially leading to significant visual impairment. The recent adoption of alternative drug delivery options has led to the development of new sustained-delivery corticosteroid systems, able to manage successfully chronic noninfectious posterior uveitis. The treatment goal is to target the site of inflammation with low dose of corticosteroids, delivered over an extended period of time, to minimize the cumulative damage resulting from repeated recurrences, reducing both injections frequency and ocular side effects. This article will review the pharmacology and preliminary clinical data of the 0.18 mg fluocinolone acetonide intravitreal implant (YUTIQ™), to show its efficacy and safety in the treatment of noninfectious posterior uveitis.

Report this publication

Statistics

Seen <100 times